Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    11001068 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Withdrawn Neoadjuvant Bevacizumab and Carboplatin Followed by Concurrent Bevacizumab, Carboplatin and Radiotherapy in the Primary Treatment of Cervix Cancer
Condition: Cervical Cancer
Interventions: Drug: Bevacizumab;   Drug: Carboplatin;   Radiation: Radiation Therapy

Indicates status has not been verified in more than two years